変装した幹細胞
1Dana-Farber Cancer Institute, Boston, MA, USA.
まとめ
エピトープ編集は 標的型がん免疫療法を 強化するための新しい戦略です このアプローチは標的を正確に修正し 癌治療の効果を高めます
科学分野:
- がん免疫学
- 分子生物学
- 遺伝子工学
背景:
- 癌に対する免疫療法は 癌と戦うために 免疫系を活用することを目的としています
- 現在の免疫療法では 標的の特異性や免疫回避といった課題に直面しています
- エピトープ編集は,これらの制限を克服するための潜在的な解決策です.
研究 の 目的:
- 癌の免疫療法におけるエピトープ編集の可能性を探るため
- ターゲットエピトープの修正が治療の有効性を改善する方法を調査する.
- 精密腫瘍学の有効なツールとしてエピトープ編集を確立する.
主な方法:
- CRISPR-Cas9または同様の遺伝子編集技術を使用しています
- 癌細胞の特定の標的エピトープを特定し,変更する.
- 免疫細胞の認識と死に対するエピトープ変化の影響を評価する.
主要な成果:
- 癌細胞の標的エピトープの成功変異が実証された.
- 編集された癌細胞に対する免疫細胞の認識と細胞毒性の強化を示した.
- 臨床前モデルの治療結果の改善を示した.
結論:
- エピトープ編集は 次世代のがん免疫療法を開発するための 強力な戦略です
- この技術により 免疫認識を正確に制御でき より効果的ながん治療が可能になります
- エピトープ編集に関するさらなる研究は,精密ながん治療に大きな希望をもたらします.
関連する概念動画
Embryonic Stem Cells
3.5K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
3.5K
Stem Cell Culture
5.2K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.2K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Source And Potency Of Stem Cells
4.8K
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
4.8K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K


